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Exchange Transfusion as Treatment for Rasburicase Induced Methemoglobinemia
in a Glucose-6-Phosphate Dehydrogenase Deficient Patient
To the Editor: A recent letter in this journal described
methemoglobinemia and hemolysis due to rasburicase in a patient
with glucose-6-phosphate dehydrogenase (G6PD) deficiency [1].
We would like to report on the management of a patient with
rasburicase induced methemoglobinemia and G6PD deficiency. DS
is a 12-year-old Laotian male who presented with a white blood cell
count of 533,900/mm3 (89% blasts), hemoglobin 10.1 mg/dL, and
platelets of 27,000/mm3 and was diagnosed with T-cell Acute
Lymphoblastic Leukemia. Metabolic labs were normal except BUN
23 mg/dL, LDH 4,698 mg/dL, and uric acid 22.1 mg/dL. Rasburi-
case (ElitekTM) 10.5 mg (0.2 mg/kg) was administered. One hour
later his uric acid was 18.1 mg/dL, and 10 hr later it was<0.2 mg/dL.
During leukopheresis, his oxygen saturation level dropped to the 70s
and did not improve with supplemental oxygen. Methemoglobin
levels were found to be 7–10%. He received two doses of methylene
blue, and a repeat methemoglobin level was 7% with persistently
low oxygen saturation. A G6PD assay showed activity of 3 U/gm
Hgb (normal 4.6–13.5 U/gm Hgb). He underwent a double-volume
exchange transfusion, after which his methemoglobin level was 0%
and his oxygen saturation was normal. Both remained normal
throughout the remainder of his induction therapy.
Methemoglobin is generated when hemoglobin iron is oxidized
from the ferrous (Fe2þ) to the ferric (Fe3þ) state. Administered
methylene blue is converted to leukomethylene blue by the
NADPH-dependent methemoglobin reductase system, which then
transfers an electron to ferric iron reducing it to ferrous iron [2]. As
evidenced in our patient, this mechanism is ineffective in G6PD-
deficient patients because of the inability to generate sufficient
NADPH to drive the reaction [2,3]. Therefore, the only effective
treatment is direct removal of the methemoglobin by exchange
transfusion [4]. In our patient, this treatment was successful in
lowering his methemoglobin level and resolving his hypoxia.
Rasburicase has been reported to cause methemoglobinemia and
hemolysis [1]. The package insert contains a recommendation for
screening high-risk patients for G6PD deficiency prior to initiating
rasburicase. However, in clinically emergent cases involving severe
hyperuricemia and impending renal damage, waiting for a G6PD
assay is usually not practical. Therefore, in patients at high risk for
G6PD deficiency, we advocate close monitoring for hypoxia and
methemoglobinemia when administering rasburicase. If the patient
becomes hypoxic due to methemoglobinemia, avoid the use of
methylene blue as this may precipitate a hemolytic anemia in a
G6PD deficient patient while not treating the methemoglobinemia.
Instead exchange transfusion is needed to remove the methemo-
globinemia and improve oxygen saturations.
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